Kirby McInerney LLP Announces Investigation Against Anika Therapeutics, Inc. (ANIK) on Behalf of Investors

Core Insights - Anika Therapeutics is under investigation by Kirby McInerney LLP for potential violations of federal securities laws and unlawful business practices [1][3] Company Performance - On July 30, 2025, Anika announced topline results from its clinical trial of Hyalofast, which is a resorbable hyaluronic acid scaffold for cartilage repair [3] - The clinical trial showed consistent improvements in treated patients compared to microfracture, but did not meet its pre-specified co-primary endpoints due to a higher dropout rate and missed visits during COVID, leading to reduced evaluable sample size [3] - Following the announcement, Anika's share price fell by $3.06, approximately 27.42%, closing at $8.10 per share on the same day [3]